LEONETTI, ALESSANDRO
LEONETTI, ALESSANDRO
Dipartimento di Medicina e Chirurgia
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
2021-01-01 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
2021-01-01 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
2022-01-01 Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
2021-01-01 Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E.
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)
2018-01-01 Leonetti, A.; Zielli, T.; Buti, S.
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib
2021-01-01 Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M.
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition?
2019-01-01 Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E.
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
2020-01-01 Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M.
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
2020-01-01 Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S.
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
2021-01-01 Buti, S.; Perrone, F.; Zielli, T.; Mazzaschi, G.; Casartelli, C.; Leonetti, A.; Milanese, G.; Silva, M.; Eufrasia Ledda, R.; Musolino, A.; Pucci, F.; Bersanelli, M.; Tiseo, M.
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
2017-01-01 Leonetti, A.; Leonardi, F.; Bersanelli, M.; Buti, S.
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
2020-01-01 Leonetti, A.; Facchinetti, F.; Zielli, T.; Brianti, E.; Tiseo, M.
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis
2021-01-01 Leonetti, A.; Capula, M.; Minari, R.; Mazzaschi, G.; Gregori, A.; El Hassouni, B.; Papini, F.; Bordi, P.; Verze, M.; Avan, A.; Tiseo, M.; Giovannetti, E.
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens
2022-01-01 Mazzaschi, G; Verze, M; Tognazzi, D; Lorusso, B; Minari, R; Pluchino, M; Trentini, F; Manini, M; Bordi, P; Leonetti, A; Perrone, F; Coriano, M; Casali, M; Toscani, I; Cosenza, A; Ferri, L; Buti, S; Sverzellati, N; Quaini, F; Tiseo, M
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
2022-01-01 Mazzaschi, G.; Moron Dalla Tor, L.; Milanese, G.; Balbi, M.; Tognazzi, D.; Lorusso, B.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Ledda, R. E.; Bordi, P.; Leonetti, A.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy
2016-01-01 Buti, S.; Leonetti, A.; Dallatomasina, A.; Bersanelli, M.
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
2021-01-01 Papini, F.; Sundaresan, J.; Leonetti, A.; Tiseo, M.; Rolfo, C.; Peters, G. J.; Giovannetti, E.
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
2020-01-01 Bergonzini, C.; Leonetti, A.; Tiseo, M.; Giovannetti, E.; Peters, G. J.
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression
2021-01-01 Leonetti, A.; Giudice, G. C.; Perrone, F.; Tiseo, M.; Giovannetti, E.
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS
2022-01-01 Mazzaschi, G; Moron Dalla Tor, L; Balbi, M; Milanese, G; Leo, L; Dalla Valle, B; Trentini, F; Lorusso, B; Verzè, M; Pluchino, M; Minari, R; Perrone, F; Bordi, P; Leonetti, A; Buti, S; Silva, M; Roti, G; Sverzellati, N; Quaini, F; Tiseo, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy | 1-gen-2021 | Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M. | |
| 17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors | 1-gen-2022 | Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? | 1-gen-2021 | Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E. | |
| Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) | 1-gen-2018 | Leonetti, A.; Zielli, T.; Buti, S. | |
| Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib | 1-gen-2021 | Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M. | |
| Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? | 1-gen-2019 | Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E. | |
| Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study | 1-gen-2020 | Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M. | |
| Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy | 1-gen-2020 | Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S. | |
| Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study | 1-gen-2021 | Buti, S.; Perrone, F.; Zielli, T.; Mazzaschi, G.; Casartelli, C.; Leonetti, A.; Milanese, G.; Silva, M.; Eufrasia Ledda, R.; Musolino, A.; Pucci, F.; Bersanelli, M.; Tiseo, M. | |
| Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma | 1-gen-2017 | Leonetti, A.; Leonardi, F.; Bersanelli, M.; Buti, S. | |
| COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors | 1-gen-2020 | Leonetti, A.; Facchinetti, F.; Zielli, T.; Brianti, E.; Tiseo, M. | |
| Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis | 1-gen-2021 | Leonetti, A.; Capula, M.; Minari, R.; Mazzaschi, G.; Gregori, A.; El Hassouni, B.; Papini, F.; Bordi, P.; Verze, M.; Avan, A.; Tiseo, M.; Giovannetti, E. | |
| Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens | 1-gen-2022 | Mazzaschi, G; Verze, M; Tognazzi, D; Lorusso, B; Minari, R; Pluchino, M; Trentini, F; Manini, M; Bordi, P; Leonetti, A; Perrone, F; Coriano, M; Casali, M; Toscani, I; Cosenza, A; Ferri, L; Buti, S; Sverzellati, N; Quaini, F; Tiseo, M | |
| Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer | 1-gen-2022 | Mazzaschi, G.; Moron Dalla Tor, L.; Milanese, G.; Balbi, M.; Tognazzi, D.; Lorusso, B.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Ledda, R. E.; Bordi, P.; Leonetti, A.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy | 1-gen-2016 | Buti, S.; Leonetti, A.; Dallatomasina, A.; Bersanelli, M. | |
| Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? | 1-gen-2021 | Papini, F.; Sundaresan, J.; Leonetti, A.; Tiseo, M.; Rolfo, C.; Peters, G. J.; Giovannetti, E. | |
| Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? | 1-gen-2020 | Bergonzini, C.; Leonetti, A.; Tiseo, M.; Giovannetti, E.; Peters, G. J. | |
| Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression | 1-gen-2021 | Leonetti, A.; Giudice, G. C.; Perrone, F.; Tiseo, M.; Giovannetti, E. | |
| LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS | 1-gen-2022 | Mazzaschi, G; Moron Dalla Tor, L; Balbi, M; Milanese, G; Leo, L; Dalla Valle, B; Trentini, F; Lorusso, B; Verzè, M; Pluchino, M; Minari, R; Perrone, F; Bordi, P; Leonetti, A; Buti, S; Silva, M; Roti, G; Sverzellati, N; Quaini, F; Tiseo, M |